HIV Vaccines (Clinical Trials)

Interim Results of HGP-30 AIDS Vaccine Study Announced

Published in Vaccine Weekly, November 11th, 1996

Cel-Sci Corp., Alexandria, Virginia, announced interim results of its Phase I safety study with the HGP-30 AIDS vaccine in HIV infected individuals.

AIDS Research Alliance, West Hollywood, California, has been conducting the 24 patient study. The interim analysis at week ten showed the first two administrations of the HGP-30 AIDS vaccine to be safe in HIV infected patients.

Proof of safety of HGP-30 in HIV infected individuals is the primary goal of this study. When evaluated as a group, disease stabilization during the ten week evaluation period was seen in patients with a CD4 count between 300 and 750. The number of patients with a CD4 count...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1996-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry